目的探讨钙敏感受体在缺氧诱导的大鼠肺动脉平滑肌细胞(PAMSCs)增殖中的信号转导途径及其作用。方法Ⅱ型胶原酶消化法提取、培养大鼠PAMSCs。通过缺氧培养箱内(93%N2,2%O2,5%CO2)培养24h的方法复制细胞缺氧模型。应用Western印迹技术分析不同处理情况下增殖细胞核抗原(PCNA)及磷酸化的细胞外调解蛋白激酶1,2(p-ERK1,2)蛋白在PAMSCs的相对表达量;采用流式细胞技术检测不同处理因素对细胞增殖周期及增殖指数的影响,应用5-溴脱氧尿嘧啶核苷(BrdU)掺人法分析不同处理因素对细胞DNA合成的影响。结果缺氧引起PAMSCs的PCNA(0.5284-0.028)及p-ERK1,2(1.12±0.05、0.91±0.06)表达水平上调,均显著高于对照组的0.243±0.025及0.47±0.03、0.40±0.03(均P〈0.05),BrdU掺入量(143.3±4.2)和细胞增殖指数(12.5±0.9)也显著高于对照组的(100.0±5.4和7.5±1.2)(均P〈0.05);钙敏感受体激动剂GdCl,能够放大缺氧的上述作用(0.770±0.039,1.50±0.06,1.61±0.05,187.4±3.9,19.8±0.6)(与对缺氧组比较,均P〈0.05),但此效应可以被ERK1,2通路阻断剂PD98059抑制(0.441±0.020,0.71±0.07,0.72±0.06,115.5±4.0,9.3±1.1)(与缺氧+GdCl3组比较,均P〈0.05)。结论CaSR通过ERK1,2信号通路参与缺氧诱导的大鼠PAMSCs增殖。
Objective To explore the cell signal transduction pathway of calcium-sensing receptor (CaSR) mediated hypoxia-induced proliferation of rat pulmonary artery smooth muscle cells (PASMCs). Methods The expressions of proliferating cell nuclear antigen (PCNA) and extracellular signal-regulated protein kinase 1,2 (ERK1, 2) were analyzed by Western blot. Cell proliferation was tested by a 5-bromo- 2-deoxyuridine(BrdU) incorporation assay. Cell cycle and proliferation index (PI) were analyzed by flow cytometry. Results Hypoxia significantly increased the expression of PCNA (0. 528 ± 0. 028), p-ERK1,2 ( 1.12 ±0.05, 0.91±0. 06), BrdU incorporation ( 143.3±4. 2) and cell proliferation index ( 12. 5 ±0. 9) (all P 〈 0. 05, versus control group, 0. 243 ± 0. 025, 0.47 ± 0. 03, 0.40 ± 0. 03, 100.0±5.4, 7.5 ± 1.2). Gadolinium chloride ( GdC13, a CaSR agonist) amplified the effect of hypoxia ( 0. 770± 0. 039, 1.50±0.06, 1.61 ±0.05, 187.4 ±3.9, 19.8±0.6, all P〈0.05). PD98059 (a MEK1 inhibitor) decreased the up-regulation of PCNA expression, BrdU incorporation and the increase of cell proliferation index induced by hypoxia and GdC13 in PASMCs (0. 441 ± 0. 020, 0. 71 ±0. 07, 0. 72 ±0. 06, 115.5 ± 4. 0, 9. 3 ±1.1, all P 〈 0. 05 ) . Conclusion Calcium-sensing receptor mediates hypoxia-indueed proliferation of rat pulmonary artery smooth muscle cells through ERK1,2 pathways.